Biofrontera Inc. is on the Cruelty-Free Investing usage of animals list because they undertake pre-clinical studies on animals to examine the safety profile of their medications.
The company stated in the following report that they exploit animals for product testing.
“BF-1 is a highly selective serotonin receptor inhibitor. This substance is being developed as a tablet for migraine prophylaxis. BF-1 has shown excellent results in mouse models of migraine development.” (Page 6) Read the full document
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription drug for the treatment of impetigo. The company was founded in 1997 and is headquartered in Woburn, Massachusetts.
Company Website: https://www.biofrontera.com/en